1363383-31-6 Usage
Uses
Used in Organic Synthesis:
3-Amino-oxetane-3-carboxylic acid Methyl ester serves as a key building block in organic synthesis, facilitating the creation of a wide array of chemical compounds.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 3-Amino-oxetane-3-carboxylic acid Methyl ester is utilized as an intermediate for the synthesis of various pharmaceuticals, contributing to the development of new drugs and therapeutic agents.
Used in Pharmaceutical Production:
3-Amino-oxetane-3-carboxylic acid Methyl ester is employed as a crucial component in the production of drugs, owing to its ability to be incorporated into the molecular structures of biologically active molecules, thereby enhancing their efficacy and potential applications in medicine.
Used in the Synthesis of Biologically Active Compounds:
3-aMino-oxetane-3-carboxylic acid Methyl ester is also used in the synthesis of biologically active compounds, highlighting its significance in the discovery and creation of novel molecules with potential applications in biological and medical research.
Check Digit Verification of cas no
The CAS Registry Mumber 1363383-31-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,6,3,3,8 and 3 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1363383-31:
(9*1)+(8*3)+(7*6)+(6*3)+(5*3)+(4*8)+(3*3)+(2*3)+(1*1)=156
156 % 10 = 6
So 1363383-31-6 is a valid CAS Registry Number.
1363383-31-6Relevant academic research and scientific papers
CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE
-
Paragraph 0001190; 0001194, (2018/01/17)
Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.
DIHYDROPTERIDINONES II
-
Page/Page column 76; 77, (2014/09/03)
The present invention relates to spiroheterocycl-dihydropyhmidines, their use as modulators of γ-secretase and to pharmaceutical compositions containing said compounds. In particular, the present invention relates to compounds which interfere with γ-secretase and/or its substrate and therefore modulate the formation of Αβ peptides.
DIHYDROPTERIDINONES II
-
Paragraph 0378-0380, (2013/09/12)
The present invention relates to spiroheterocycl-dihydropyrimidines, their use as modulators of γ-secretase and to pharmaceutical compositions containing said compounds. In particular, the present invention relates to compounds which interfere with γ-secretase and/or its substrate and therefore modulate the formation of Aβ peptides.
